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SHORT REPORT Open Access
Anogenital Human Papillomavirus Infection
and HIV Infection Outcomes Among
Peruvian Transgender Women:
Results from a Cohort Study
Brandon Brown,1* Jerome T. Galea,2,3 Gita Byraiah,4 Tonia Poteat,5 Segundo R. Leon,2 Gino Calvo,3
Hugo Sa´nchez,3 Thomas Coates,6 and Jeffrey D. Klausner6
Abstract
Latin American transgender women are highly vulnerable to HIV infection, and although much is known about
factors associated with HIV infection in this population, little is known about the association of human papilloma
virus (HPV) with HIV infection. We investigated anogenital HPV and cumulative HIV incidence among 68, initially
HIV uninfected, Peruvian transgender women enrolled into a 2-year, prospective cohort study: 95.6% had at least
one anogenital HPV genotype at baseline, 19.1% had visible anogenital warts, and 6.0% became infected with
HIV over the course of the study. Due to the high anogenital HPV prevalence, this population would likely beneﬁt
from early immunization with the HPV vaccine.
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Background
Worldwide, transgender women are disproportionally
affected by HIV, with an odds 49 times the general
population.1 In Peru, HIV prevalence in transgender
women is estimated at 30%.2 Although HIV incidence
and human papilloma virus (HPV) acquisition have
been increasingly studied in Peru,2–4 less is known
about the risks of acquiring HIV when already infected
with HPV and the role that visible anogenital warts
may play.5,6 Speciﬁcally among transgender women,
there may be a heightened risk for HPV infection
and development of anogenital warts as a result of re-
ceptive anal intercourse.7 HPV infection is associated
with the development of anogenital cancers, and coin-
fection with HIV accelerates the development of HPV-
associated cancer.8,9
In a systematic review of the literature on HPV in-
fection and acquisition of HIV infection across multi-
ple populations, most studies found an association
between HPV infection and subsequent infection with
HIV, with nearly double the risk of acquiringHIV infec-
tion in those previously infected with HPV.10 The sug-
gested mechanism of biological plausibility given for
this association is epithelial disruption of the genital
tract by HPV infection, which could facilitate HIV ac-
quisition.11 Studies among men who have sex with men
(MSM) have demonstrated an association between
HPV-related anogenital warts and HIV acquisition.5
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A study by Chin-Hong et al. found that the presence of
two or more HPV genotypes in the anus was associ-
ated with HIV seroconversion.6 However, no studies
have assessed the risks of incident HIV infection in
transgender women based on anogenital HPV infec-
tion and the presence of anogenital warts. The study
objectives were to (1) describe baseline prevalence
for anogenital warts and anogenital HPV types in
this population, (2) determine the incidence of ano-
genital HPV and HIV infection over the course of
the study period, and (3) explore the association be-
tween baseline anogenital HPV types and incident
HIV infection.
Study Overview
We used data from a larger cohort study of 600 HIV
uninfected Peruvian transgender women and MSM en-
rolled in Project VIVA, a longitudinal 2-year study de-
scribed elsewhere.12 The study was designed to recruit
both transgender women and MSM, with an expected
enrollment of 5–20% transgender women based on
the gender distribution at the recruitment venue. The
relationship between baseline anogenital wart presence,
anogenital HPV infection, and incident HIV infection
in initially HIV uninfected transgender women was
assessed.
Methods
Using convenience sampling, participants were recruited
from Epicentro Salud, a community health center pro-
viding care to MSM and transgender women in Lima,
Peru. Study inclusion criteria were as follows: born ana-
tomically male, aged 18–40 years, self-reported anal sex
with a male within 12 months before study enrollment,
resident of metropolitan Lima with no plans to move
during the study period, and being HIV uninfected
at enrollment. Participants were excluded if they had
previously participated in an HIV or HPV vaccine trial.
Details of baseline methodology were previously pub-
lished.7,12,13 For the following analysis, only participants
who identiﬁed as a gender different from male were
included. The 2-year prospective clinical study con-
sisted of twice-yearly surveys and specimen collection.
The computerized survey was self-administered and
addressed sexual and perisexual behaviors and prac-
tices, whereas the clinical examination included testing
for HPV and HIV infection. The study was approved
by institutional review boards at the University of
California, Los Angeles (UCLA) and Impacta Salud y
Educacio´n in Peru.
Specimen collection and testing
At the initial visit, participants were asked about his-
tory of anogenital warts. During the clinical examina-
tion, pre-moistened Dacron swabs were used to collect
specimens from the penis coronal sulcus/glans, shaft,
scrotum, and anus and then pooled into one sample
per participant for a single HPV test result per person.
That was done to increase cost-effectiveness, following
a previously established protocol to deﬁne presence of
anogenital infection.14 Samples were stored at80C be-
fore transfer to the testing laboratory. At the Mofﬁtt
Cancer Center Laboratory, DNA was extracted using
the QIAamp Media MDx Kit (Qiagen), followed by
PCR and HPV genotyping. Samples that tested positive
for b-globin or at least one HPV genotype were consid-
ered adequate and were included in the analysis (overall
b-globin positivity 98%). The Linear Array assay (Roche
Diagnostics) was used for detection of 37 HPV geno-
types classiﬁed as high risk (oncogenic; HPV 16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) or low
risk (nononcogenic; HPV 6, 11, 26, 40, 42, 53, 54, 55,
61, 62, 64, 66, 67, 69, 70, 71, 72, 73, 81, 82, 82 subtype
IS39, 83, 84, and 89 [formerly CP6108]).15 HIV infection
status was ascertained using the Determine HIV-1/2
Combo Ag/Ab test (Alere, Inc.) and conﬁrmed by indi-
rect immunoﬂuorescence assay (in-house test, Peruvian
National Institute of Health); individuals testing positive
were linked to the national HIV program for free care.
Data analysis
Univariate descriptive statistics were used to examine
baseline variables, prevalence of HPV infection and
anogenital warts, and incident HIV infection. Chi-
square tests were conducted to assess the association
of anogenital warts with incident HIV. All analyses
were conducted using Stata Version 12.0 (Stata Corp.).
Results
Of 68 transgender women, the mean age was 25.2 years
(range 18–39), with 79.4% completing secondary school
and 20.4% completing university education. Over half
(52.9%) had a current partner and 42.7% had anal sex
for the ﬁrst time before 14 years of age. Sex partners
of transgender women were mostly men (95.1%), but
some (4.5%) transgender women reported sex with
men and women. During anal sex with men, the ma-
jority of participants were exclusively (34.4%) or
mostly (52.5%) receptive, with 6.6% equally receptive
and insertive. Transgender women had a mean fre-
quency of 72 episodes of anal intercourse during the
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previous 6 months, with 87.5% reporting condom use
during their last anal sex encounter. The majority of
participants (82.1%) received money or favors for
sex in the past 6 months. Nearly half of participants
(42.2%) reported sex under the inﬂuence of alcohol in
the past month. Use of rectal douches in relation to re-
ceptive anal intercourse was reported by nearly half
(47%) of transgender women. Approximately one-
third (36.9%) of participants had heard of HPV before
participating in this study.
Anogenital warts were present in 19.1% of transgen-
der women at the baseline visit, with the majority of
those having anal warts only (Fig. 1). The prevalence
of any anogenital HPV infection was 95.6%. Vaccine-
FIG. 1. Study diagram of Peruvian transgender women enrolled in the VIVA Study in Lima, Peru (one person
missing from ﬁnal follow-up).
FIG. 2. Prevalence of individual HPV genotypes, those in quadrivalent HPV vaccine, those in nonavalent HPV
vaccine, and any HPV genotype (37 total types) among 68 Peruvian transgender women. HPV, human
papilloma virus.
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related genotypes included HPV6 (17.6%), HPV11
(7.4%), HPV16 (16.2%), HPV18 (1.5%), HPV31
(7.4%), HPV33 (2.9%), HPV45 (5.9%), HPV52 (5.9%),
and HPV58 (16.8%). Transgender women had an 82.3%
prevalence of LRHPV (HPV types 6 and 11), 58.8%
HRHPV (HPV types 16, 18, 31, 33, 45, 52, and 58), and
66.2% had more than one HPV type (Fig. 2). Of those
who reported condom use during their last episode of
anal intercourse, 84.6% had the presence of any HPV sub-
type. HIV was acquired by 6.0% (n=4) of transgender
women across the 2-year study period. Of the four trans-
gender women who tested HIV positive, one had anogen-
ital warts ( p=0.55).
Conclusions
Anogenital warts were common among transgender
women in this sample and the overwhelming majority
had prevalent anogenital HPV infection, despite reports
of condom use at last anal sex. Consistent condom use
has been shown to increase anogenital HPV infection
clearance rates in other populations by preventing rein-
fection.16 The high rates of HPV infection among trans-
gender women in our study may have been related to
less than 100% condom use, the frequency of anal inter-
course, and potential exposure to a variety of HPV geno-
types while engaged in sex work. Although a high
percentage of transgender women in the study were
infected with more than one HPV genotype, being
infected with multiple genotypes was not associated
with HIV seroconversion as found in a previous study.6
An overall annual HIV incidence rate of 3% among
transgender women in Peru is very high and consistent
with the heavy burden of HIV among transgender
women.2 Although reported condom use for anal sex
at the last sexual encounter was high and higher than
in previous studies with transgender women in Lima
(87.5% vs. 75.1%), condom promotion alone has not
been sufﬁcient to curb the HIV epidemic in this popula-
tion.2 More than half of the transgender women in
the study were infected with high-risk HPV types that
are targeted by the nonavalent HPV vaccine. Thus,
those women could have beneﬁted from immunization
before exposure. NewHIV infections and high prevalent
anogential HPV in the setting of higher than typical
condom use highlight the need for additional prevention
measures, such as the HPV vaccine and HIV pre-
exposure prophylaxis.
Education will also be key to reduce HPV transmis-
sion. A minority of transgender women had heard of
HPV infection before participating in this study. Previ-
ously reported data from this cohort demonstrated that
transgender women were four times as likely as MSM
to believe that HPV infection had been resolved
when there were no longer visible genital warts.13 Iden-
tifying and addressing those knowledge gaps are essen-
tial components of HIV and sexually transmitted
infection risk reduction strategies.
Our study was limited by the use of visual inspection
for the ascertainment of anogenital warts. Although cost-
prohibitive in this study, biopsy is the gold standard for
diagnosis of HPV-related warts and would have been
able to conﬁrm the lesions. In addition, since we pooled
samples from the penis coronal sulcus/glans, shaft, scro-
tum, and anus, we could not identify the exact anatomical
site of HPV infection. Due the use of convenience sam-
pling, our ﬁndings may not be generalizable to beyond
the study population. The small sample size of transgen-
der women reduced the power of the study to detect sig-
niﬁcant relationships that may have been present.
We report on prevalence of anogenital HPV infec-
tion and anogenital warts among transgender women,
and to our knowledge we are the ﬁrst to test an associ-
ation between anogenital warts and HIV incidence
among transgender women. Future studies should ex-
plore hypothesized relationships between HIV infection
and the location of HPV infection in this population
compared with MSM and natal female sex workers,
and control for other potential confounders including
use of gender-afﬁrming hormones, douching, and lon-
ger term condom use. Larger sample sizes and the use
of biopsy conﬁrmation for anogenital warts would also
strengthen future studies.
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